Fibrocell Science (NASDAQ:FCSC) Stock Rating Upgraded by ValuEngine

Fibrocell Science (NASDAQ:FCSC) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, June 4th, ValuEngine reports.

Other research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Fibrocell Science from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a research note on Friday, February 8th. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Fibrocell Science in a report on Thursday, March 28th.

FCSC traded up $0.03 during trading on Tuesday, reaching $1.90. The company’s stock had a trading volume of 35,039 shares, compared to its average volume of 65,709. The company has a debt-to-equity ratio of 0.85, a current ratio of 3.59 and a quick ratio of 3.59. The stock has a fifty day simple moving average of $1.95. Fibrocell Science has a 1 year low of $1.45 and a 1 year high of $3.28.

Fibrocell Science (NASDAQ:FCSC) last released its earnings results on Wednesday, May 15th. The company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.07). On average, equities analysts anticipate that Fibrocell Science will post -1.31 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Fibrocell Science stock. Apis Capital Advisors LLC purchased a new position in shares of Fibrocell Science Inc (NASDAQ:FCSC) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 25,000 shares of the company’s stock, valued at approximately $48,000. Apis Capital Advisors LLC owned about 0.26% of Fibrocell Science at the end of the most recent reporting period. Hedge funds and other institutional investors own 28.04% of the company’s stock.

Fibrocell Science Company Profile

Fibrocell Science, Inc, an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions.

Further Reading: How is inflation measured?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with's FREE daily email newsletter.